Ipamorelin · Research brief

Is GHRP-2 Worth It? Ipamorelin vs GHRP 6 Compared

Real Peptides Research TeamEditorial

Updated September 24, 20268 min read

54 WORDS

Short answer

Ask which growth hormone secretagogue is strongest and you'll get a ranking. Ask which is cleanest and you'll get the same ranking, flipped. Both framings skip what the primary literature on Ipamorelin vs GHRP 6 vs GHRP-2 actually measured: not peak growth hormone output, but how much ACTH, cortisol and prolactin arrived with it.

Key takeaways

Ipamorelin, GHRP-2 and GHRP-6 all act on GHS-R1a, the ghrelin receptor, so differences between them are about selectivity rather than a different mechanism of growth hormone release.
Raun and colleagues reported in the European Journal of Endocrinology in 1998 that Ipamorelin released growth hormone without a significant ACTH or cortisol response at doses far above the GH-releasing threshold.
GHRP-2, also known as pralmorelin, is the only one of the three developed as a growth hormone deficiency diagnostic agent, which is why its human pituitary hormone data is the deepest of the group.
GHRP-6 produces the strongest appetite response, which makes it a useful orexigenic research tool and a poor choice when food intake would confound the endpoint.
In Ipamorelin vs GHRP 6 comparisons, the deciding variable is the width of the margin between the GH-releasing dose and the ACTH-releasing dose, not the absolute cortisol number.
CJC-1295, Tesamorelin and Sermorelin are GHRH analogues acting on a different receptor, so they complement a GHRP rather than compete with one.

Our team supplies all three compounds to labs running secretagogue selectivity work, and one question shows up constantly. Is GHRP-2 worth it when Ipamorelin exists?

What is the difference between Ipamorelin vs GHRP 6?

Ipamorelin vs GHRP 6 is a selectivity comparison, not a potency contest. Both bind GHS-R1a, the ghrelin receptor. GHRP-6 is a hexapeptide that strongly drives appetite signalling and is reported to raise cortisol and prolactin alongside growth hormone. Ipamorelin is a pentapeptide reported to release growth hormone without those off-target increases.

The oversimplification worth killing: selective does not mean weak. Raun and colleagues, introducing Ipamorelin in the European Journal of Endocrinology in 1998, described growth hormone release comparable to the older GHRPs with no significant ACTH or cortisol response at doses well above the GH-releasing threshold. What follows covers receptor biology, the cortisol and prolactin data, the appetite divide, and how each compound behaves next to a GHRH analogue.

Same receptor, three very different molecules

All three are ghrelin mimetics. They bind GHS-R1a, the growth hormone secretagogue receptor, which sits on pituitary somatotrophs and in the hypothalamic arcuate nucleus. Binding that receptor triggers a pulse of endogenous growth hormone rather than supplying hormone from outside, which is why the class is studied as a model of pulsatile GH physiology rather than as a replacement approach.

GHRP-6 is the first-generation hexapeptide that came out of Cyril Bowers' enkephalin-derived secretagogue work. It's a potent GHS-R1a agonist, and because the arcuate receptor population it activates is the same one native ghrelin uses to signal hunger, it produces a pronounced increase in food intake in animal studies.

GHRP-2, also called pralmorelin, is a second-generation hexapeptide. It's the only member of this group developed as a clinical diagnostic agent, with a GHRP-2 stimulation test used to assess growth hormone deficiency. That history matters: GHRP-2's pituitary hormone profile has been characterised in human studies more thoroughly than GHRP-6's ever was.

Ipamorelin is a pentapeptide, structurally the outlier of the three, and was engineered for receptor selectivity rather than raw amplitude.

Researchers who contact us almost always arrive with a potency question. The literature keeps answering a selectivity question instead.

Cortisol, prolactin and appetite: what the research reports

The headline finding is Ipamorelin's dose separation. Raun and colleagues reported that Ipamorelin released growth hormone with potency comparable to GHRP-6 while producing no significant ACTH or cortisol response, even at doses many times higher than those needed for maximal GH release. Studies of GHRP-2 and GHRP-6 consistently report modest, dose-dependent rises in ACTH, cortisol and prolactin travelling alongside the GH pulse.

Here's the nuance most comparisons flatten. The difference isn't that GHRP-2 floods the system with stress hormones. It doesn't. Reported increases are modest and generally stay within physiological range. The real difference is margin. With Ipamorelin, the gap between the GH-releasing dose and the ACTH-releasing dose is wide. With the hexapeptides, those two curves sit close together. That margin, not the absolute cortisol figure, is what a selectivity study is actually measuring.

Appetite is the cleanest practical divider of the three. GHRP-6 drives food intake hard, GHRP-2 does so less consistently, and Ipamorelin is reported to have minimal orexigenic effect. In any body-composition model that's not a footnote. Food intake shifting independently of GH contaminates the endpoint completely, which is why a GHRP-6 arm often needs pair-feeding controls that an Ipamorelin arm doesn't.

Which GHRP is best depends entirely on the endpoint

So, is GHRP-2 worth it? In a research setting, yes, with a specific justification. GHRP-2 produces a strong GH pulse, carries the deepest human characterisation of the three thanks to its diagnostic development, and its prolactin and cortisol response is a measurable variable rather than a defect. If a study is examining the full pituitary response to ghrelin receptor activation, GHRP-2's lack of selectivity is the entire point.

If the study needs growth hormone isolated from everything else, that answer inverts. Ipamorelin vs GHRP 6 in a metabolic model is barely a contest, because GHRP-6 introduces two confounds that Ipamorelin doesn't: appetite drive and a broader pituitary signature.

Then there's the GHRH question. Searches comparing GHRP 6 vs CJC-1295 Ipamorelin usually come from a category error. CJC-1295 isn't a rival to either compound. It's a GHRH analogue acting on a separate receptor, and the literature describes synergistic growth hormone release when a GHRH analogue and a GHS-R1a agonist are combined, because they pull on different arms of the same axis. Tesamorelin and Sermorelin sit in that same GHRH family.

Across the labs our team supplies, selectivity beats amplitude as the deciding factor almost every time.

Ipamorelin vs GHRP 6 vs GHRP-2: side-by-side

This table condenses what the published literature reports across the three axes researchers actually select on. Nothing here is dosing or administration guidance, and all three compounds are research-use-only materials rather than approved drugs.

Compound	Structure and receptor target	Reported cortisol and prolactin signal	Reported appetite effect	Bottom line for research use
Ipamorelin	Pentapeptide, selective GHS-R1a agonist	No significant ACTH or cortisol rise reported at doses well above the GH-releasing threshold	Minimal orexigenic activity reported	The default when the endpoint requires growth hormone isolated from stress-axis and feeding confounds
GHRP-2 (pralmorelin)	Hexapeptide, potent GHS-R1a agonist	Modest, dose-dependent increases in ACTH, cortisol and prolactin reported in human studies	Present but generally less pronounced than GHRP-6	Worth it when the study wants a strong GH pulse plus a characterised multi-hormone response, or needs human-study comparability
GHRP-6	Hexapeptide, first-generation GHS-R1a agonist	Cortisol and prolactin increases reported alongside GH release	Strong and reproducible increase in food intake	Now most useful as an appetite and ghrelin-signalling tool rather than a clean GH probe

What If: Research Design Scenarios

What if a study needs growth hormone effects separated from appetite changes?

Ipamorelin is the compound the selectivity literature supports for that design. GHRP-6's orexigenic drive means any change in adiposity, lean mass or glucose handling could be explained by food intake rather than the GH axis, and controlling for that requires pair-feeding arms most designs can't afford. GHRP-2 sits in the middle, with a less consistent appetite signal but still a measurable one. The cleaner the selectivity, the fewer control arms the protocol needs.

What if a protocol combines a GHRP with CJC-1295 or another GHRH analogue?

Expect a larger growth hormone pulse than either compound produces alone, and design the assay timing around that. GHRH analogues act on the GHRH receptor while GHRPs act on GHS-R1a, and the literature describes synergy when both arms of the somatotropic axis are stimulated together. That synergy also amplifies whatever off-target signal the GHRP carries, so a GHRP-2 or GHRP-6 pairing should include cortisol and prolactin sampling that an Ipamorelin pairing may not require.

What if the material received doesn't match the expected specification?

Stop and check the certificate of analysis against the vial before anything else. Lyophilised peptides should arrive as a white to off-white cake or powder; colour, partial collapse or moisture in the vial all point to a cold chain or sealing failure. Verify the stated molecular identity, the HPLC purity figure and the mass spectrometry confirmation against the batch document, not against a generic product page. A compound whose identity can't be confirmed on paper isn't a usable reagent regardless of how it looks.

The unglamorous truth about ranking these three

Here's the honest answer: there is no single best GHRP, and the forum habit of ranking them on a strength ladder is the reason so many comparisons go wrong. Ipamorelin vs GHRP 6 isn't a fight one of them wins. It's a trade between selectivity and breadth of pituitary response, and the correct answer flips depending on what's being measured. If pressed for a default, ours is Ipamorelin, because most modern research questions want GH isolated. GHRP-6 has quietly become more interesting as an appetite and ghrelin-signalling tool than as a growth hormone probe.

For laboratories sourcing these materials, Real Peptides supplies Ipamorelin, GHRP-2 and GHRP-6 as individual research compounds, alongside the GHRH-side comparators including CJC-1295 No DAC and the CJC-1295 with Ipamorelin and Tesamorelin with Ipamorelin research pairings. Every batch is small-batch synthesised with third-party analysis, and the certificates of analysis are published for verification before procurement. Background on the selectivity data sits on our Ipamorelin research page, and the wider research catalog covers adjacent compounds.

Ipamorelin vs GHRP 6 gets argued as a strength question because strength is easy to rank and selectivity isn't. But the reason Ipamorelin exists at all is that the first generation of secretagogues worked too broadly, hitting the stress axis and the feeding circuit on the way to the somatotrophs. Narrowing a molecule's reach is harder pharmacology than amplifying its output, and it's the variable that determines whether a growth hormone study measures growth hormone or measures everything else that moved at the same time.

References

Peer-reviewed sources on Ipamorelin indexed in PubMed, listed for research context. Real Peptides supplies Ipamorelin for laboratory research use only.

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior, 2024. PMID 39043357. doi:10.1016/j.physbeh.2024.114644
The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Animal reproduction science, 2024. PMID 38996787. doi:10.1016/j.anireprosci.2024.107550
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 2014. PMID 25331030. doi:10.1007/s00384-014-2030-8
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 2012. PMID 27186127. doi:10.2147/JEP.S35396
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics, 2009. PMID 19289567. doi:10.1124/jpet.108.149211
Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters, 2004. PMID 15665799
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002. PMID 12168778. doi:10.14670/HH-17.707
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001. PMID 11735244. doi:10.1054/ghir.2001.0239

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

In research terms, yes, when the design justifies it. GHRP-2 produces a strong growth hormone pulse and has the deepest human characterisation of the three ghrelin mimetics because of its development as a GH deficiency diagnostic agent. If a study needs GH isolated from cortisol and prolactin movement, Ipamorelin is the better selection.

GHRP-2, also called pralmorelin, is a synthetic hexapeptide growth hormone secretagogue that binds GHS-R1a, the ghrelin receptor, on pituitary somatotrophs. Research describes it triggering a pulse of endogenous growth hormone, with modest dose-dependent increases in ACTH, cortisol and prolactin reported alongside. It is a research-use-only compound, not an approved drug.

Real Peptides doesn't provide dosing, administration or preparation guidance, because GHRP-2 is supplied strictly for laboratory research and isn't for human use. What we do supply is the concentration framework: the certificate of analysis states the exact milligram content per vial, which is the basis for any mg-per-mL calculation a research protocol requires.

For selectivity-driven research designs, Ipamorelin is usually the strongest choice of the three. It's a pentapeptide GHS-R1a agonist reported to release growth hormone without significant ACTH or cortisol response and with minimal appetite effect, which removes two major confounds from metabolic and body-composition endpoints.

Yes, and that's the core distinction. GHRP-6 is reported to raise cortisol and prolactin alongside growth hormone, while Ipamorelin was introduced in the European Journal of Endocrinology in 1998 as showing no significant ACTH or cortisol response even at doses well above the GH-releasing threshold. The separation between those dose curves is the measurable difference.

There isn't one best GHRP, only a best fit for a given endpoint. Ipamorelin suits designs needing growth hormone isolated from stress-axis and feeding effects. GHRP-2 suits studies wanting a strong pulse plus a characterised multi-hormone response. GHRP-6 is now most useful as an appetite and ghrelin-signalling tool rather than a clean GH probe.

Forum discussion of Ipamorelin vs GHRP 2 tends to rank the compounds by perceived strength and describe GHRP-2 as harder-hitting. The published literature frames the same comparison differently, around receptor selectivity and the margin between GH-releasing and ACTH-releasing doses. Anecdotal rankings and selectivity data are answering two different questions.

CJC-1295 isn't in the same class. It's a GHRH analogue acting on the GHRH receptor, while GHRP-6 and Ipamorelin are ghrelin mimetics acting on GHS-R1a. The literature describes synergistic growth hormone release when a GHRH analogue and a GHS-R1a agonist are studied together, because they stimulate separate arms of the somatotropic axis.

Lyophilised research peptides are typically held at minus 20 degrees Celsius, protected from light and moisture, with freeze-thaw cycling minimised. Peptides are proteins, so temperature excursions can degrade the structure without any visible change to the cake. Storage specifications for each batch appear on its certificate of analysis.

Check the batch-specific certificate of analysis before procurement, not just a generic product claim. A usable certificate shows HPLC purity, mass spectrometry confirmation of molecular identity and the peptide content of the vial. Real Peptides publishes certificates of analysis for verification, and every batch is small-batch synthesised with third-party testing.

Not exactly. All three compounds bind the same receptor, GHS-R1a. Selectivity here describes how wide the dose gap is between growth hormone release and secondary pituitary responses such as ACTH, cortisol and prolactin. Ipamorelin's reported advantage is the width of that margin rather than a fundamentally different mechanism of action.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA